TLX — Telix Pharmaceuticals Limited
Is TLX overbought or oversold? Here is the current MarketMoodz read.
Telix Pharmaceuticals Limited (TLX) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $8.85. The rating moved from Overbought to Strong Oversold on November 12, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$8.85
- Last changeMoved from Overbought to Strong Oversold on November 12, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Telix Pharmaceuticals Limited (TLX) is a specialty radiopharmaceutical company with a portfolio positioned at the intersection of diagnostic and therapeutic oncology. Near‑term upside depends on successful commercialization of late‑stage assets, partner distribution execution, and clarity on reimbursement pathways; conversely, funding needs, regulatory shifts (including recent CMS program integrity activity), and clinical setbacks present material downside. Given the balance of commercialization opportunity against execution and reimbursement risk, the stock is expected to trade in a relative consolidation pattern absent clear clinical or regulatory catalysts.
Key factors
- Established radiopharmaceutical pipeline targeting diagnostic and therapeutic oncology niches with several late‑stage commercialization opportunities
- Favorable structural demand for specialty radiopharma from specialty pharmacies, infusion centers and biopharma service channels
- Progress on commercialization and partner/distributor relationships that can drive near‑term revenue growth if uptake in target indications materializes
- Mixed sector environment: defensive capital is flowing to large‑cap pharma while smaller specialty names may see selective interest tied to clear clinical/regulatory wins
- Cash runway and financing posture (capital needs could affect dilution risk) — funding status is a key near‑term determinant of execution
- Regulatory and reimbursement environment (including CMS program integrity and Medicare Advantage dynamics) will materially influence commercial economics
Risks
- Reimbursement uncertainty and evolving Medicare Advantage policy could constrain pricing and adoption for diagnostic/therapeutic radiopharmaceuticals
- Clinical or regulatory setbacks for lead programs that delay approvals or limit label/population, reducing near‑term revenue visibility
- Commercial execution risk: slower-than-expected adoption, limited specialty distribution capacity, or constrained referral patterns
- Manufacturing, supply chain or scale-up challenges for radiopharmaceutical production impacting product availability
- Capital markets pressure and potential equity dilution if additional financing is required to fund operations or launch activities
- Competitive pressure from larger pharma entrants, adjacent diagnostic modalities, or alternative therapeutic pathways
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TLX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.